HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Concord Drugs Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 22 filings·Updated 12 Aug 2026
Showing 10 of 22 filings.
12 Aug 20261 filing
Company UpdateNewspaper Publication

Copy of News-paper publications for quarterly results ended 30th June 2026.

Filed 19:06View Source
10 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Concord Drugs approves unaudited standalone and consolidated 30 June 2026 results; notes Limited Review Reports

Financial results and audit notes

  • Board approved unaudited standalone and consolidated financial results for quarter ended 30 June 2026.
  • Board noted Limited Review Reports issued by the statutory auditors.
  • Results to be published in newspapers as per SEBI LODR requirements.
  • Results available on Concord Drugs website and BSE website.
Filed 17:31View Source
13 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Dematerialisation actions completed; securities listed; physical certificates mutilated and registered-owner updated

Dematerialisation compliance

  • Dematerialisation actions were completed within 15 days of receipt of certificates.
  • The dematerialised securities are listed on the stock exchanges.
  • Physical certificates for dematerialisation were mutilated and cancelled; depository named as registered owner.
Filed 18:50View Source
27 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Closure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March, 2026.

Filed 16:52View Source
17 Feb 20261 filing
Company UpdateNewspaper Publication

News Paper publication of Q3 results

Filed 14:37View Source
2 Feb 20261 filing
Board Meeting

Concord Drugs Ltd - 538965 - Board Meeting Intimation for Quarterly Results

🗓️ Meeting Details

  • Board meeting scheduled for 14 February 2026 to approve unaudited standalone and consolidated financial results.
  • Financial results pertain to the quarter ended 31 December 2025.
Filed 16:59View Source
20 Jan 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg 74(5) of SEBI (DP) regulations

Filed 13:16View Source
25 Nov 20253 filings
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Koni Reddy

Filed 09:44View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy

Filed 09:43View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Manoj Kumar Reddy

Filed 09:42View Source
Showing 10 of 22 filings